LMR Partners LLP Takes $219,000 Position in Alto Neuroscience, Inc. (NYSE:ANRO)

LMR Partners LLP acquired a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 51,700 shares of the company’s stock, valued at approximately $219,000. LMR Partners LLP owned about 0.19% of Alto Neuroscience as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wells Fargo & Company MN raised its holdings in shares of Alto Neuroscience by 40.0% in the fourth quarter. Wells Fargo & Company MN now owns 10,989 shares of the company’s stock valued at $46,000 after purchasing an additional 3,139 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Alto Neuroscience by 31.3% in the fourth quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after purchasing an additional 3,629 shares during the last quarter. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $74,000. Jane Street Group LLC raised its holdings in shares of Alto Neuroscience by 72.0% in the fourth quarter. Jane Street Group LLC now owns 18,600 shares of the company’s stock valued at $79,000 after purchasing an additional 7,783 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in shares of Alto Neuroscience by 24.4% in the fourth quarter. Rhumbline Advisers now owns 25,556 shares of the company’s stock valued at $108,000 after purchasing an additional 5,008 shares during the last quarter.

Alto Neuroscience Price Performance

Shares of ANRO opened at $2.22 on Thursday. The company has a market cap of $60.10 million, a price-to-earnings ratio of -0.87 and a beta of 1.87. Alto Neuroscience, Inc. has a 1-year low of $1.60 and a 1-year high of $17.55. The company’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $3.46. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.06. On average, research analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ANRO shares. HC Wainwright initiated coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They issued a “buy” rating and a $10.00 price objective on the stock. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Alto Neuroscience currently has an average rating of “Moderate Buy” and an average target price of $15.40.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.